Pancreatic safety of incretin-based drugs–FDA and EMA assessment
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
A guide to clinical management and public health response for hand, foot and mouth disease (HFMD).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A decreased risk of colorectal adenomas and colorectal carcinoma is a consistent finding with a potential for a survival benefit for colorectal carcinoma.1784–1790”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1789]
In the citing paper
“Although pancreatic adverse events are difficult to completely rule out, an assessment by the FDA and the EMA concluded that a causal association between incretin-based drugs and pancreatitis or pancreatic cancer is inconsistent with the current data (77).”
From Safety of Semaglutide (2021) · cites this paper as [77]
Citations
Cites
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Butler, A. E., Campbell-Thompson, M., Gurlo, T., Dawson, D. W., Atkinson, M., & Butler, P. C. (2013) · Diabetes · doi:10.2337/db12-1686 · Cited by 457
Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies
Engel, S. S., Round, E., Golm, G. T., Kaufman, K. D., & Goldstein, B. J. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0024-0 · Cited by 123
Cited by
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
“observational data sets (32), as well as from two large cardiovascular trials with DPP-4 inhibitors (28–30), have found no statistically increased rates of pancreatic disease.”
BackgroundDeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.19 · Cited by 2,611
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetologia · doi:10.1007/s00125-014-3460-0 · Cited by 694
“While this is reasonable, emerging data from large observational datasets [32], as well as from two large cardiovascular trials with DPP4 inhibitors [28–30], have found no statistically increased rates of pancreatic disease.”
ResultObesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management
Pati, S., Irfan, W., Jameel, A., Ahmed, S., & Shahid, R. K. (2023) · Cancers · doi:10.3390/cancers15020485 · Cited by 677
“A handful of preclinical studies suggest their association with thyroid and pancreatic cancer [151,152].”
BackgroundPharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors
Mulvihill, E. E., & Drucker, D. J. (2014) · Endocrine Reviews · doi:10.1210/er.2014-1035 · Cited by 609
“safety data (12) surrounding the use of DPP4 inhibitors.”
BackgroundFilippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Glucagon-like peptide 1 in health and disease
Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0016-2 · Cited by 543
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Nauck, M. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12591 · Cited by 429
“Retrospective analysis of AE reporting databases also correlated GLP-1RAs with an increased risk of pancreatitis [50]; however, as mentioned previously, an extensive review by the FDA and EMA in 2014 concluded that, studies so far do not show a causal link between incretin-based drugs and either pancreatitis or pancre…”
BackgroundResultPhysiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
Deacon, C. F. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00080 · Cited by 428
Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system
Klemann, C., Wagner, L., Stephan, M., & von Hörsten, S. (2016) · Clinical and Experimental Immunology · doi:10.1111/cei.12781 · Cited by 425
Gilbert, M. P., & Pratley, R. E. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00178 · Cited by 407
“Extensive, independent studies by the Food and Drug Administration which examined the potential for increased risk of pancreatitis and pancreatic cancer, showed no evidence for “pancreatic toxicity” of these two classes of medications (96).”
BackgroundPharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.86 · Cited by 398
Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus
Deacon, C. F. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0399-8 · Cited by 398
Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
Hinnen, D. (2017) · Diabetes Spectrum · doi:10.2337/ds16-0026 · Cited by 394
“The FDA and the European Medicines Agency concluded that available data were not consistent with a causal association between incretin-based therapies and pancreatitis, but data on the pancreatic effects continue to be monitored (41).”
BackgroundReview: Diabetes, Obesity, and Cancer—Pathophysiology and Clinical Implications
Lega, I. C., & Lipscombe, L. L. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz014 · Cited by 364
“While there were initial concerns about an increased risk of pancreatic cancer with incretin-based drugs and medullary thyroid cancer with GLP-1 receptor agonists, these effects have not been confirmed in recent studies (112–114).”
Smits, M. M., & Van Raalte, D. H. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645563 · Cited by 332
“Oral semaglutide 3 mg 101 (77) 3 (2) 7 (5) 3 (2) 2 (2) 0 0 2 (2)”
BackgroundReview of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists
Madsbad, S. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12596 · Cited by 305
“The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have agreed that assertions concerning a causal association between incretin-based drugs and pancreatitis or pancreatic cancer, as expressed recently in the scientific literature and in the media, are inconsistent with current data; howe…”
BackgroundResultAmerican Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s004 · Cited by 285
Modifiable and non-modifiable risk factors for pancreatic cancer: A review
Midha, S., Chawla, S., & Garg, P. K. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.07.022 · Cited by 281
Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention
Hostalek, U., Gwilt, M., & Hildemann, S. (2015) · Drugs · doi:10.1007/s40265-015-0416-8 · Cited by 278
Aroda, V. R. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13162 · Cited by 253
“Several other safety areas of interest have emerged in the development of GLP-1 RAs.”
BackgroundInfluentialDiamant, M., Nauck, M. A., Shaginian, R., Malone, J. K., Cleall, S., Reaney, M., de Vries, D., Hoogwerf, B. J., MacConell, L., Wolffenbuttel, B. H. R., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0876 · Cited by 228
Glucagon‐like peptide‐1 receptor agonists in type 2 diabetes treatment: are they all the same?
Gentilella, R., Pechtner, V., Corcos, A., & Consoli, A. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3070 · Cited by 227
“30,31,33,36,38,52,54,60,61,63,65,72,81,91,96,97 The US Food and Drug Administration and European Medicines Agency recently evaluated the available preclinical and clinical data relating to pancreatic risk: neither agency found evidence to support a causal association between incretin‐based drugs and pancreatitis or pa…”
BackgroundElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Cusi, K., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s004 · Cited by 222
Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment
Van Gaal, L., & Scheen, A. (2015) · Diabetes Care · doi:10.2337/dc14-1630 · Cited by 221
“Food and Drug Administration (FDA) and the European Medicines Agency (EMA), despite a reassuring position statement, continue to investigate this safety signal (54).”
BackgroundMakrilakis, K. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16152720 · Cited by 216
“However, based also on small histopathologic studies that pointed to a marked expansion of the exocrine and endocrine pancreatic compartments with the use of incretin-based therapies, the former being accompanied by increased proliferation and dysplasia and the latter by α-cell hyperplasia with the potential for evolu…”
BackgroundElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Cusi, K. J., Ekhlaspour, L., Fleming, T. K., Hilliard, M. E., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc24-s004 · Cited by 258
Comparative review of dipeptidyl peptidase‐4 inhibitors and sulphonylureas
Deacon, C. F., & Lebovitz, H. E. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12610 · Cited by 213
“Regulatory authorities in the USA and the European Union have carried out independent reviews of all data [72], finding no evidence to support a causal relationship between incretin therapies and pancreatitis, while major diabetes societies (the ADA, EASD and International Diabetes Federation) have not modified curren…”
BackgroundCancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing?
Klil-Drori, A. J., Azoulay, L., & Pollak, M. N. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.120 · Cited by 210
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Cusi, K., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s004 · Cited by 205
Frias, J. P., Bonora, E., Nevarez Ruiz, L., Li, Y. G., Yu, Z., Milicevic, Z., Malik, R., Bethel, M. A., & Cox, D. A. (2021) · Diabetes Care · doi:10.2337/dc20-1473 · Cited by 199
“safety (5,6), and experience with stepwise dose escalation to optimize GI tolerability (7), combined with a persistent need for therapies to maintain glycemic control, prompted study of higher onceweekly doses (3.”
Backgroundvan Baar, M. J. B., van Ruiten, C. C., Muskiet, M. H. A., van Bloemendaal, L., IJzerman, R. G., & van Raalte, D. H. (2018) · Diabetes Care · doi:10.2337/dc18-0588 · Cited by 199
“Although the incidence is low, usage is associated with an increased risk of pancreatitis (50,68).”
BackgroundDPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature
Saini, K., Sharma, S., & Khan, Y. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1130625 · Cited by 208
“FDA and the European Medicines Agency (Egan et al., 2014).”
InfluentialPharmacotherapy of type 2 diabetes: An update
Upadhyay, J., Polyzos, S. A., Perakakis, N., Thakkar, B., Paschou, S. A., Katsiki, N., Underwood, P., Park, K.-H., Seufert, J., Kang, E. S., et al. (2018) · Metabolism · doi:10.1016/j.metabol.2017.08.010 · Cited by 187
Battle of GLP-1 delivery technologies
Yu, M., Benjamin, M. M., Srinivasan, S., Morin, E. E., Shishatskaya, E. I., Schwendeman, S. P., & Schwendeman, A. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.009 · Cited by 180
Pharmacotherapy of type 2 diabetes: An update and future directions
DeMarsilis, A. J., Reddy, N., Boutari, C., Filippaios, A., Sternthal, E., Katsiki, N., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155332 · Cited by 185
Evolution of pharmacological obesity treatments: focus on adverse side‐effect profiles
Krentz, A. J., Fujioka, K., & Hompesch, M. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12657 · Cited by 168
“Liraglutide has a generally good safety record; a possible class-effect increase in risk of pancreatitis and pancreatic cancer has not been corroborated by the FDA and EMA [132].”
Sitagliptin: A Review in Type 2 Diabetes
Scott, L. J. (2017) · Drugs · doi:10.1007/s40265-016-0686-9 · Cited by 170
Storgaard, H., Cold, F., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12885 · Cited by 155
“of data on AP from CV safety studies of incretin-based therapies in 2014.(5) Large international multicentre population-based cohort stud-”
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s004 · Cited by 147
Demographics, Epidemiology, and Inheritance of Pancreatic Ductal Adenocarcinoma
Yeo, T. P. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.12.002 · Cited by 164
Lombardi, L., Genio, V. D., Alberício, F., & Williams, D. R. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00989 · Cited by 147
Inflammation meets metabolic disease: Gut feeling mediated by GLP-1
Zietek, T., & Rath, E. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00154 · Cited by 131
“Since the relationship remains unclear, both the Endocrinologic and Metabolic Drugs Advisory Committee and the FDA’s Division of Metabolism and Endocrinology Products concluded that there is not sufficient evidence available to conclude that incretin-based therapies cause acute pancreatitis or pancreatic cancer (65).”
BackgroundThe safety of gliptins : updated data in 2018
Scheen, A. J. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1444027 · Cited by 126
“itate meta-analyses, and accumulation of further knowledge regarding these signals in the future’ [43].”
BackgroundUser’s guide to mechanism of action and clinical use of GLP-1 receptor agonists
Shaefer, C. F., Kushner, P., & Aguilar, R. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1090295 · Cited by 128
“An assessment of pancreatic safety of incretin-based drugs conducted by the FDA and the European Medicines Agency found no evidence for a causal association between incretin-based drugs and pancreatitis or pancreatic cancer [52].”
BackgroundDPP-4 Inhibition and the Path to Clinical Proof
Åhrén, B. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00376 · Cited by 138
Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies
Thrasher, J. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.04.004 · Cited by 112
“There have been postmarketing reports of acute pancreatitis in patients treated with DPP-4 inhibitors; however, no clear causal association has been established.(74) Prompt discontinuation of DPP-4 inhibitor treatment is recommended if pancreatitis is suspected.”
BackgroundPharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies
Thrasher, J. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.009 · Cited by 112
“There have been postmarketing reports of acute pancreatitis in patients treated with DPP-4 inhibitors; however, no clear causal association has been established.(74) Prompt discontinuation of DPP-4 inhibitor treatment is recommended if pancreatitis is suspected.”
BackgroundClinical Considerations for Use of Initial Combination Therapy in Type 2 Diabetes
Cahn, A., & Cefalu, W. T. (2016) · Diabetes Care · doi:10.2337/dcs15-3007 · Cited by 118
Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study
Azoulay, L., Filion, K. B., Platt, R. W., Dahl, M., Dormuth, C. R., Clemens, K. K., Durand, M., Juurlink, D. N., Targownik, L. E., Turin, T. C., et al. (2016) · BMJ · doi:10.1136/bmj.i581 · Cited by 120
Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis
Azoulay, L., Filion, K. B., Platt, R. W., Dahl, M., Dormuth, C. R., Clemens, K. K., Durand, M., Hu, N., Juurlink, D. N., Paterson, J. M., et al. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.1522 · Cited by 120
Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes
Scheen, A. J. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1006625 · Cited by 126
“The FDA and the EMA have not reached a final conclusion at this time regarding such a causal relationship and both agencies continue to investigate the safety signal of acute pancreatitis as well as the potential risk of pancreatic cancer [72].”
BackgroundInfluentialNever waste a good crisis: confronting reproducibility in translational research
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.08.006 · Cited by 117
GLP ‐1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond
Ryan, D., & Acosta, A. (2015) · Obesity · doi:10.1002/oby.21107 · Cited by 112
“Although the totality of the data that have been reviewed provides reassurance, pancreatitis will continue to be considered a risk associated with these drugs until more data are available; both agencies continue to investigate this safety signal” (125).”
BackgroundGantz, I., Chen, M., Suryawanshi, S., Ntabadde, C., Shah, S., O’Neill, E. A., Engel, S. S., Kaufman, K. D., & Lai, E. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0593-8 · Cited by 108
“In past years, the topic of pancreatic safety of incretin therapies has been raised [15].”
BackgroundGodinho, R., Mega, C., Teixeira-de-Lemos, E., Carvalho, E., Teixeira, F., Fernandes, R., & Reis, F. (2015) · Journal of Diabetes Research · doi:10.1155/2015/806979 · Cited by 109
“In addition, FDA and EMA independently evaluated the safety data from postmarketing reports of pancreatitis and pancreatic cancer in patients using incretin-based drugs, analysing both animal and clinical information available, and concluded that a causal association between incretin-based drugs and pancreatitis or pa…”
BackgroundExenatide: pharmacokinetics, clinical use, and future directions
Knop, F. K., Brønden, A., & Vilsbøll, T. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1282463 · Cited by 105
“The conclusion was that a causal relationship between incretin-based therapies and pancreatitis and pancreatic cancer could not be supported by current data [45].”
BackgroundDiabetes and pancreatic cancer: Exploring the two-way traffic
Roy, A., Sahoo, J., Kamalanathan, S., Naik, D., Mohan, P., & Kalayarasan, R. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i30.4939 · Cited by 118
Toki, S., Goleniewska, K., Reiss, S., Zhang, J., Bloodworth, M. H., Stier, M. T., Zhou, W., Newcomb, D. C., Ware, L. B., Stanwood, G. D., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.11.043 · Cited by 104
“Glucagon-like peptide 1 receptor (GLP-1R) agonists, such as liraglutide and exenatide, are approved by the US Food and Drug Administration (FDA) for treatment of type 2 diabetes (T2D).(14,15) Several studies report that GLP-1R agonists had anti-inflammatory effects in patients with multiple disorders, including T2D.”
Scheen, A. J. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.978289 · Cited by 106
“Although the totality of the data that have been reviewed provides reassurance, pancreatitis will continue to be considered a risk associated with these drugs until more data are available; both agencies continue to investigate this safety signal as well as the potential risk of pancreatic cancer [138].”
BackgroundRehman, M. B., Tudrej, B. V., Soustre, J., Buisson, M., Archambault, P., Pouchain, D., Vaillant-Roussel, H., Gueyffier, F., Faillie, J., Pérault-Pochat, M.-C., et al. (2016) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.09.005 · Cited by 110
Nishimura, R., Kato, H., Kisanuki, K., Oh, A., Hiroi, S., Onishi, Y., Guelfucci, F., & Shimasaki, Y. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-025806 · Cited by 104
Optical Control of Insulin Secretion Using an Incretin Switch
Broichhagen, J., Podewin, T., Meyer‐Berg, H., von Ohlen, Y., Johnston, N. R., Jones, B. J., Bloom, S. R., Rutter, G. A., Hoffmann‐Röder, A., Hodson, D. J., et al. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201506384 · Cited by 111
Pharmacologic Treatment of Type 2 Diabetes
Tran, L., Zielinski, A., Roach, A. H., Jende, J. A., Householder, A. M., Cole, E. E., Atway, S. A., Amornyard, M., Accursi, M. L., Shieh, S. W., et al. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028014558289 · Cited by 121
“Until further research is available, these agencies state that information in the package insert is an accurate reflection of the current literature.(141) DPP4-Is have few drug interactions because the main route of elimination for this drug class is renal or fecal.”
BackgroundLiraglutide for Type 2 diabetes and obesity: a 2015 update
Iepsen, E. W., Torekov, S. S., & Holst, J. J. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2015.1054810 · Cited by 101
“Pancreatic safety of GLP-1 RAs has been reviewed in February 2014 by regulatory authorities, and according to literature review both the FDA and the EMA concluded that a causal association between incretin-based therapies and pancreatitis and pancreatic cancer are inconsistent [107].”
BackgroundRisk of pancreatitis in patients treated with incretin-based therapies
Meier, J. J., & Nauck, M. A. (2014) · Diabetologia · doi:10.1007/s00125-014-3231-y · Cited by 101
“Retrospective analyses of health insurance claims databases or adverse event reporting systems [4] are associated with methodological uncertainties and have yielded controversial results [2, 5].”
BackgroundManagement of diabetes in older adults
Sesti, G., Antonelli Incalzi, R., Bonora, E., Consoli, A., Giaccari, A., Maggi, S., Paolisso, G., Purrello, F., Vendemiale, G., & Ferrara, N. (2018) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.11.007 · Cited by 84
“until the results of new studies will be available [73].”
BackgroundDo GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-analysis
Piccoli, G. F., Mesquita, L. A., Stein, C., Aziz, M., Zoldan, M., Degobi, N. A. H., Spiazzi, B. F., Lopes Junior, G. L., Colpani, V., & Gerchman, F. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa891 · Cited by 81
Toki, S., Newcomb, D. C., Printz, R. L., Cahill, K. N., Boyd, K. L., Niswender, K. D., & Peebles, R. S. (2021) · Allergy · doi:10.1111/all.14879 · Cited by 88
Drug Repositioning for Diabetes Based on 'Omics' Data Mining
Zhang, M., Luo, H., Xi, Z., & Rogaeva, E. (2015) · PLOS ONE · doi:10.1371/journal.pone.0126082 · Cited by 95
“Avandia from GSK, for example, was found to be associated with risk of heart attack [1], resulting in a recommendation of suspension by European Medicines Agency (EMA) in 2010.”
BackgroundNauck, M. A., Jensen, T. J., Rosenkilde, C., Calanna, S., Buse, J. B., & the LEADER Publication Committee on behalf of the LEADER Trial Investigators (2018) · Diabetes Care · doi:10.2337/dc17-1825 · Cited by 94
“Results from large, prospective clinical trials may help clarify a potential risk for neoplasms with GLP-1RAs or other glucose-lowering medications (26).”
BackgroundNewer GLP-1 receptor agonists and obesity-diabetes
Brown, E. E., Cuthbertson, D. J., & Wilding, J. P. H. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.009 · Cited by 111
Incretins in obesity and diabetes
Chia, C. W., & Egan, J. M. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14211 · Cited by 93
Advances in the management of type 2 diabetes in adults
Galindo, R. J., Trujillo, J. M., Wang, C. C. L., & McCoy, R. G. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2022-000372 · Cited by 110
Gut adaptation after metabolic surgery and its influences on the brain, liver and cancer
Sinclair, P., Brennan, D. J., & le Roux, C. W. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0057-y · Cited by 91
Ayoub, M., Chela, H. K., Amin, N. A., Hunter, R., Anwar, J., Tahan, V., & Daglilar, E. S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14030944 · Cited by 94
“Both the FDA and the EMA were not able to reach a final conclusion about such an association, however, they both agreed that the totality of the available data at that time was reassuring [85].”
InfluentialTen years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus
Sesti, G., Avogaro, A., Belcastro, S., Bonora, B. M., Croci, M., Daniele, G., Dauriz, M., Dotta, F., Formichi, C., Frontoni, S., et al. (2019) · Acta Diabetologica · doi:10.1007/s00592-018-1271-3 · Cited by 94
Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features
Lyseng-Williamson, K. A. (2019) · Clinical Drug Investigation · doi:10.1007/s40261-019-00826-0 · Cited by 87
Steinberg, W. M., Buse, J. B., Ghorbani, M. L. M., Ørsted, D. D., Nauck, M. A., the LEADER Steering Committee, & on behalf of the LEADER Trial Investigators (2017) · Diabetes Care · doi:10.2337/dc16-2747 · Cited by 87
“risk associated with incretin-based drugs until further data are available (7).”
BackgroundSuliman, M., Buckley, A., Al Tikriti, A., Tan, T., le Roux, C. W., Lessan, N., & Barakat, M. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13672 · Cited by 86
“In 2014, the European Medicines Agency (EMA) and the FDA concluded that an association between the incretin drugs and acute pancreatitis or pancreatic cancer is inconsistent with current data; however, both agencies also agreed that until further information becomes available, pancreatitis will continue to be consider…”
BackgroundLind, M., Hirsch, I. B., Tuomilehto, J., Dahlqvist, S., Ahrén, B., Torffvit, O., Attvall, S., Ekelund, M., Filipsson, K., Tengmark, B.-O., et al. (2015) · BMJ · doi:10.1136/bmj.h5364 · Cited by 82
The Ascending GLP-1 Road From Clinical Safety to Reduction of Cardiovascular Complications
Drucker, D. J. (2018) · Diabetes · doi:10.2337/dbi18-0008 · Cited by 78
“The possibility that therapy with GLP-1R agonists might predispose susceptible individuals to the development of acute or chronic pancreatitis or pancreatic cancer has received considerable scrutiny (73).”
BackgroundMushrooms of the Genus Ganoderma Used to Treat Diabetes and Insulin Resistance
Wińska, K., Mączka, W. K., Gabryelska, K., & Grabarczyk, M. (2019) · Molecules · doi:10.3390/molecules24224075 · Cited by 90
“, exenatide, liraglutide, lixisenatide) [10].”
Incretin physiology and pathophysiology from an A sian perspective
Cho, Y. M. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12305 · Cited by 80
Steinberg, W. M., Rosenstock, J., Wadden, T. A., Donsmark, M., Jensen, C. B., & DeVries, J. H. (2017) · Diabetes Care · doi:10.2337/dc16-2684 · Cited by 76
“Food and Drug Administration (FDA) and the European Medicines Agency concluded that the data at the time did not support a causal relationship between incretin-based drugs and AP (4).”
Drug induced acute pancreatitis: Does it exist?
Tenner, S. M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i44.16529 · Cited by 82
Wang, J., & Kim, C. H. (2022) · Endocrine Research · doi:10.1080/07435800.2021.1955255 · Cited by 74
The Effects of Major Mushroom Bioactive Compounds on Mechanisms That Control Blood Glucose Level
Јovanović, J. A., Mihailović, M., Uskoković, A. S., Grdović, N., Dinić, S., & Vidaković, M. (2021) · Journal of Fungi · doi:10.3390/jof7010058 · Cited by 82
“The most common side-effects reported are headache, nasopharyngitis, and upper respiratory tract infection [32].”
BackgroundOverbeek, J. A., Bakker, M., van der Heijden, A. A. W. A., van Herk‐Sukel, M. P. P., Herings, R. M. C., & Nijpels, G. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3004 · Cited by 71
“In 2014, a joint study was published in the New England Journal of Medicine, stating that the agencies had not yet reached a final conclusion regarding a possible relationship.(4) Since then, several literature reviews have been conducted regarding incretin‐based drugs and pancreatic cancer.”
BackgroundDipeptidyl‐peptidase‐4 inhibitors and pancreatic cancer: a cohort study
Gokhale, M., Buse, J. B., Gray, C. L., Pate, V., Marquis, M. A., & Stürmer, T. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12379 · Cited by 72
Zou, L., Wang, P., Qian, X., Feng, L., Yu, Y., Wang, D., Jin, Q., Hou, J., Liu, Z., Ge, G., et al. (2016) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2016.11.068 · Cited by 71
“The ubiquitous expression and the enzymatic actions of DPP-IV make this enzyme to be involved in many biological or pathological processes, including the regulation of glucose metabolism (Drucker and Nauck, 2006; Egan et al., 2014).”
BackgroundDeciphering Metabolic Messages From the Gut Drives Therapeutic Innovation: The 2014 Banting Lecture
Drucker, D. J. (2015) · Diabetes · doi:10.2337/db14-1514 · Cited by 67
“Furthermore, clinical reports linking the use of GLP-1R agonists and, to a lesser extent, DPP-4i, to pancreatitis in humans have fostered a great deal of research into potential underlying mechanisms; yet, mechanisms linking GLP-1R signaling or DPP-4 inhibition to development of pancreatitis remain elusive (52).”
BackgroundClinical pharmacology of glucagon-like peptide-1 receptor agonists
Sfairopoulos, D. G., Liatis, S., Tigas, S. K., & Liberopoulos, E. N. (2018) · HORMONES · doi:10.1007/s42000-018-0038-0 · Cited by 74
Cardiovascular impact of drugs used in the treatment of diabetes
Triggle, C. R., & Ding, H. (2014) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622314546125 · Cited by 67
Hunt, J. E., Holst, J. J., Jeppesen, P. B., & Kissow, H. (2021) · Biomedicines · doi:10.3390/biomedicines9040383 · Cited by 65
“Resultantly, both the FDA and the EMA undertook evaluations of the post-marketing reports of pancreatitis and pancreatic cancer in patients using GLP-1-based drugs (41,000 participants) and re-evaluated existing and performed new toxicology reports to investigate pancreatic adverse events [85].”
Background
Metadata
- Authors
- Egan, A. G., Blind, E., Dunder, K., de Graeff, P. A., Hummer, B. T., Bourcier, T., & Rosebraugh, C.
- Affiliations
- European Medicines Agency (NL)
- Medical Products Agency (SE)
- United States Food and Drug Administration (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-02-27
- Volume
- 370
- Issue
- 9
- Pages
- 794-797
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1970905724
- Cited by
- 498
- References
- 4
- Citations by year
- 2026: 11 · 2025: 27 · 2024: 21 · 2023: 18 · 2022: 23 · 2021: 26 · 2020: 26 · 2019: 35 · 2018: 45 · 2017: 53 · 2016: 66 · 2015: 81 · 2014: 65
- FWCI
- 71.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- incretin-based drugs, drug safety assessment, FDA regulatory review, drug approval
- MeSH terms
- Animals, Diabetes Mellitus, Type 2, Drug Evaluation, Preclinical, European Union, Humans, Hypoglycemic Agents, Pancreatic Neoplasms, Pancreatitis, United States, United States Food and Drug Administration, Drug Approval, Mice, Rats, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.